AstraZeneca Pharma India shares rise over 2% after CDSCO clears Imfinzi for new cancer use

AstraZeneca Pharma India shares saw a rise after Imfinzi got approval for expanded use. The CDSCO approved it as a first-line treatment for specific endometrial cancer cases. This follows AstraZeneca's strong Q4 earnings, with a significant jump in net profit and revenue. The company attributes this to its focus on innovation.